Oncology JP Morgan Week 2025 – Marianne De Backer At JPM 2025, pharmaphorum editor-in-chief Jonah Comstock spoke with Vir Biotechnology CEO Marianne De Backer.
R&D JP Morgan 2024 – Marianne De Backer Vir Biotechnology made headlines in 2021 for its work with GlaxoSmithKline on a treatment for COVID-19, and again in 2022 for its work with the US government on influenza.
News Iambic prices its IPO, seeking to raise up to $160m AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
